MovDisordV3, PascalFrancis, Curation, bibRecord, 003860

A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients

Identifieur interne : 003860 ( PascalFrancis/Curation ); précédent : 003859; suivant : 003861

A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients

Auteurs : R. A. Hauser [États-Unis] ; E. Molho [États-Unis] ; H. Shale [États-Unis] ; S. Pedder [États-Unis] ; E. E. Dorflinger [États-Unis]

Source :

Movement disorders [ 0885-3185 ] ; 1998.

RBID : Pascal:98-0354367

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Motricité, Tolcapone, Chimiothérapie, Antiparkinsonien, Inhibiteur enzyme, Catechol O-methyltransferase, Voie orale, Sélégiline, IMAO B, Diarrhée, Nausée, Randomisation, Traitement, Toxicité, Association médicamenteuse, Adulte, Etude double insu.
Wicri :
- topic : Adulte.

English descriptors

KwdEn :
- Adult, Antiparkinson agent, Catechol O-methyltransferase, Chemotherapy, Diarrhea, Double blind study, Drug combination, Enzyme inhibitor, MAO B inhibitor, Motricity, Nausea, Oral administration, Parkinson disease, Randomization, Selegiline, Tolcapone, Toxicity, Treatment.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 13`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients`
A11	`01`	`1`		`@1 HAUSER (R. A.)`
A11	`02`	`1`		`@1 MOLHO (E.)`
A11	`03`	`1`		`@1 SHALE (H.)`
A11	`04`	`1`		`@1 PEDDER (S.)`
A11	`05`	`1`		`@1 DORFLINGER (E. E.)`
A14	`01`			`@1 University of South Florida @2 Tampa, Florida @3 USA @Z 1 aut.`
A14	`02`			`@1 Albany Medical College @2 Albany, New York @3 USA @Z 2 aut.`
A14	`03`			`@1 East Bay Neurology @2 Berkeley, California @3 USA @Z 3 aut.`
A14	`04`			`@1 Hoffmann-La Roche @2 Nutley, New Jersey @3 USA @Z 4 aut. @Z 5 aut.`
A17	`01`	`1`		`@1 Tolcapone De Novo Study Group @3 USA`
A20				`@1 643-647`
A21				`@1 1998`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000077139450040`
A44				`@0 0000 @1 © 1998 INIST-CNRS. All rights reserved.`
A45				`@0 10 ref.`
A47	`01`	`1`		`@0 98-0354367`
A60				`@1 P`
A61				`@0 A`
A64		`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C02	`01`	`X`		`@0 002B02B06`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Motricité @5 02`
C03	`02`	`X`	`ENG`	`@0 Motricity @5 02`
C03	`02`	`X`	`SPA`	`@0 Motricidad @5 02`
C03	`03`	`X`	`FRE`	`@0 Tolcapone @2 NK @2 FR @5 04`
C03	`03`	`X`	`ENG`	`@0 Tolcapone @2 NK @2 FR @5 04`
C03	`03`	`X`	`SPA`	`@0 Tolcapona @2 NK @2 FR @5 04`
C03	`04`	`X`	`FRE`	`@0 Chimiothérapie @5 05`
C03	`04`	`X`	`ENG`	`@0 Chemotherapy @5 05`
C03	`04`	`X`	`SPA`	`@0 Quimioterapia @5 05`
C03	`05`	`X`	`FRE`	`@0 Antiparkinsonien @5 06`
C03	`05`	`X`	`ENG`	`@0 Antiparkinson agent @5 06`
C03	`05`	`X`	`SPA`	`@0 Antiparkinsoniano @5 06`
C03	`06`	`X`	`FRE`	`@0 Inhibiteur enzyme @5 07`
C03	`06`	`X`	`ENG`	`@0 Enzyme inhibitor @5 07`
C03	`06`	`X`	`SPA`	`@0 Inhibidor enzima @5 07`
C03	`07`	`X`	`FRE`	`@0 Catechol O-methyltransferase @2 FE @5 08 @6 Catechol «O»-methyltransferase`
C03	`07`	`X`	`ENG`	`@0 Catechol O-methyltransferase @2 FE @5 08 @6 Catechol «O»-methyltransferase`
C03	`07`	`X`	`SPA`	`@0 Catechol O-methyltransferase @2 FE @5 08 @6 Catechol «O»-methyltransferase`
C03	`08`	`X`	`FRE`	`@0 Voie orale @5 09`
C03	`08`	`X`	`ENG`	`@0 Oral administration @5 09`
C03	`08`	`X`	`SPA`	`@0 Vía oral @5 09`
C03	`09`	`X`	`FRE`	`@0 Sélégiline @2 NK @2 FR @5 10`
C03	`09`	`X`	`ENG`	`@0 Selegiline @2 NK @2 FR @5 10`
C03	`09`	`X`	`SPA`	`@0 Selegilina @2 NK @2 FR @5 10`
C03	`10`	`X`	`FRE`	`@0 IMAO B @5 11`
C03	`10`	`X`	`ENG`	`@0 MAO B inhibitor @5 11`
C03	`10`	`X`	`SPA`	`@0 IMOA B @5 11`
C03	`11`	`X`	`FRE`	`@0 Diarrhée @5 13`
C03	`11`	`X`	`ENG`	`@0 Diarrhea @5 13`
C03	`11`	`X`	`SPA`	`@0 Diarrea @5 13`
C03	`12`	`X`	`FRE`	`@0 Nausée @5 14`
C03	`12`	`X`	`ENG`	`@0 Nausea @5 14`
C03	`12`	`X`	`SPA`	`@0 Nausea @5 14`
C03	`13`	`X`	`FRE`	`@0 Randomisation @5 16`
C03	`13`	`X`	`ENG`	`@0 Randomization @5 16`
C03	`13`	`X`	`SPA`	`@0 Aleatorización @5 16`
C03	`14`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`14`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`14`	`X`	`GER`	`@0 Aufbereiten @5 17`
C03	`14`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`15`	`X`	`FRE`	`@0 Toxicité @5 18`
C03	`15`	`X`	`ENG`	`@0 Toxicity @5 18`
C03	`15`	`X`	`GER`	`@0 Giftigkeit @5 18`
C03	`15`	`X`	`SPA`	`@0 Toxicidad @5 18`
C03	`16`	`X`	`FRE`	`@0 Association médicamenteuse @5 19`
C03	`16`	`X`	`ENG`	`@0 Drug combination @5 19`
C03	`16`	`X`	`SPA`	`@0 Asociación medicamentosa @5 19`
C03	`17`	`X`	`FRE`	`@0 Adulte @5 20`
C03	`17`	`X`	`ENG`	`@0 Adult @5 20`
C03	`17`	`X`	`SPA`	`@0 Adulto @5 20`
C03	`18`	`X`	`FRE`	`@0 Etude double insu @5 23`
C03	`18`	`X`	`ENG`	`@0 Double blind study @5 23`
C03	`18`	`X`	`SPA`	`@0 Estudio doble ciego @5 23`
C07	`01`	`X`	`FRE`	`@0 Methyltransferases @2 FE`
C07	`01`	`X`	`ENG`	`@0 Methyltransferases @2 FE`
C07	`01`	`X`	`SPA`	`@0 Methyltransferases @2 FE`
C07	`02`	`X`	`FRE`	`@0 Transferases @2 FE`
C07	`02`	`X`	`ENG`	`@0 Transferases @2 FE`
C07	`02`	`X`	`SPA`	`@0 Transferases @2 FE`
C07	`03`	`X`	`FRE`	`@0 Enzyme`
C07	`03`	`X`	`ENG`	`@0 Enzyme`
C07	`03`	`X`	`SPA`	`@0 Enzima`
C07	`04`	`X`	`FRE`	`@0 Homme`
C07	`04`	`X`	`ENG`	`@0 Human`
C07	`04`	`X`	`SPA`	`@0 Hombre`
C07	`05`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`05`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`05`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`06`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`06`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`06`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`07`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`07`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`07`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`08`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`08`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`08`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`09`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`09`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`09`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`10`	`X`	`FRE`	`@0 Appareil digestif pathologie @5 69`
C07	`10`	`X`	`ENG`	`@0 Digestive diseases @5 69`
C07	`10`	`X`	`SPA`	`@0 Aparato digestivo patología @5 69`
C07	`11`	`X`	`FRE`	`@0 Intestin pathologie @5 70`
C07	`11`	`X`	`ENG`	`@0 Intestinal disease @5 70`
C07	`11`	`X`	`SPA`	`@0 Intestino patología @5 70`
N21				`@1 236`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002F64

Links to Exploration step

Pascal:98-0354367

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients</title>
<author><name sortKey="Hauser, R A" sort="Hauser, R A" uniqKey="Hauser R" first="R. A." last="Hauser">R. A. Hauser</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Molho, E" sort="Molho, E" uniqKey="Molho E" first="E." last="Molho">E. Molho</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Albany Medical College</s1>
<s2>Albany, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Shale, H" sort="Shale, H" uniqKey="Shale H" first="H." last="Shale">H. Shale</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>East Bay Neurology</s1>
<s2>Berkeley, California</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Pedder, S" sort="Pedder, S" uniqKey="Pedder S" first="S." last="Pedder">S. Pedder</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Hoffmann-La Roche</s1>
<s2>Nutley, New Jersey</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Dorflinger, E E" sort="Dorflinger, E E" uniqKey="Dorflinger E" first="E. E." last="Dorflinger">E. E. Dorflinger</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Hoffmann-La Roche</s1>
<s2>Nutley, New Jersey</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">98-0354367</idno>
<date when="1998">1998</date>
<idno type="stanalyst">PASCAL 98-0354367 INIST</idno>
<idno type="RBID">Pascal:98-0354367</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002F64</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003860</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients</title>
<author><name sortKey="Hauser, R A" sort="Hauser, R A" uniqKey="Hauser R" first="R. A." last="Hauser">R. A. Hauser</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Molho, E" sort="Molho, E" uniqKey="Molho E" first="E." last="Molho">E. Molho</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Albany Medical College</s1>
<s2>Albany, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Shale, H" sort="Shale, H" uniqKey="Shale H" first="H." last="Shale">H. Shale</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>East Bay Neurology</s1>
<s2>Berkeley, California</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Pedder, S" sort="Pedder, S" uniqKey="Pedder S" first="S." last="Pedder">S. Pedder</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Hoffmann-La Roche</s1>
<s2>Nutley, New Jersey</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Dorflinger, E E" sort="Dorflinger, E E" uniqKey="Dorflinger E" first="E. E." last="Dorflinger">E. E. Dorflinger</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Hoffmann-La Roche</s1>
<s2>Nutley, New Jersey</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1998">1998</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Antiparkinson agent</term>
<term>Catechol O-methyltransferase</term>
<term>Chemotherapy</term>
<term>Diarrhea</term>
<term>Double blind study</term>
<term>Drug combination</term>
<term>Enzyme inhibitor</term>
<term>MAO B inhibitor</term>
<term>Motricity</term>
<term>Nausea</term>
<term>Oral administration</term>
<term>Parkinson disease</term>
<term>Randomization</term>
<term>Selegiline</term>
<term>Tolcapone</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Motricité</term>
<term>Tolcapone</term>
<term>Chimiothérapie</term>
<term>Antiparkinsonien</term>
<term>Inhibiteur enzyme</term>
<term>Catechol O-methyltransferase</term>
<term>Voie orale</term>
<term>Sélégiline</term>
<term>IMAO B</term>
<term>Diarrhée</term>
<term>Nausée</term>
<term>Randomisation</term>
<term>Traitement</term>
<term>Toxicité</term>
<term>Association médicamenteuse</term>
<term>Adulte</term>
<term>Etude double insu</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Adulte</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>13</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>HAUSER (R. A.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MOLHO (E.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>SHALE (H.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>PEDDER (S.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>DORFLINGER (E. E.)</s1>
</fA11>
<fA14 i1="01"><s1>University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Albany Medical College</s1>
<s2>Albany, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>East Bay Neurology</s1>
<s2>Berkeley, California</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Hoffmann-La Roche</s1>
<s2>Nutley, New Jersey</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>Tolcapone De Novo Study Group</s1>
<s3>USA</s3>
</fA17>
<fA20><s1>643-647</s1>
</fA20>
<fA21><s1>1998</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000077139450040</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1998 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>10 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>98-0354367</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Motricité</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Motricity</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Motricidad</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Tolcapone</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Tolcapone</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Tolcapona</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Enzyme inhibitor</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Inhibidor enzima</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Catechol O-methyltransferase</s0>
<s2>FE</s2>
<s5>08</s5>
<s6>Catechol «O»-methyltransferase</s6>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Catechol O-methyltransferase</s0>
<s2>FE</s2>
<s5>08</s5>
<s6>Catechol «O»-methyltransferase</s6>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Catechol O-methyltransferase</s0>
<s2>FE</s2>
<s5>08</s5>
<s6>Catechol «O»-methyltransferase</s6>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Voie orale</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Oral administration</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Vía oral</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Sélégiline</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Selegiline</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Selegilina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>IMAO B</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>MAO B inhibitor</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>IMOA B</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Diarrhée</s0>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Diarrhea</s0>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Diarrea</s0>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Nausée</s0>
<s5>14</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Nausea</s0>
<s5>14</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Nausea</s0>
<s5>14</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Randomisation</s0>
<s5>16</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Randomization</s0>
<s5>16</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Aleatorización</s0>
<s5>16</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="GER"><s0>Aufbereiten</s0>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>18</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>18</s5>
</fC03>
<fC03 i1="15" i2="X" l="GER"><s0>Giftigkeit</s0>
<s5>18</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>18</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Association médicamenteuse</s0>
<s5>19</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Drug combination</s0>
<s5>19</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Asociación medicamentosa</s0>
<s5>19</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Adulte</s0>
<s5>20</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Adult</s0>
<s5>20</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Adulto</s0>
<s5>20</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Etude double insu</s0>
<s5>23</s5>
</fC03>
<fC03 i1="18" i2="X" l="ENG"><s0>Double blind study</s0>
<s5>23</s5>
</fC03>
<fC03 i1="18" i2="X" l="SPA"><s0>Estudio doble ciego</s0>
<s5>23</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Methyltransferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Methyltransferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Methyltransferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Enzyme</s0>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Enzyme</s0>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enzima</s0>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Appareil digestif pathologie</s0>
<s5>69</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Digestive diseases</s0>
<s5>69</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Aparato digestivo patología</s0>
<s5>69</s5>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Intestin pathologie</s0>
<s5>70</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Intestinal disease</s0>
<s5>70</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Intestino patología</s0>
<s5>70</s5>
</fC07>
<fN21><s1>236</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003860 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 003860 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:98-0354367
   |texte=   A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients

A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients

Source :

Descripteurs français

English descriptors

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri